A randomised phase II trial of docetaxel vs docetaxel and irinotecan in patients with stage IIIb-IV non-small-cell lung cancer who failed first-line treatment

F M Wachters; H J M Groen; B Biesma; F M N H Schramel; P E Postmus; J A Stigt; E F Smit

doi:10.1038/sj.bjc.6602268

A randomised phase II trial of docetaxel vs docetaxel and irinotecan in patients with stage IIIb-IV non-small-cell lung cancer who failed first-line treatment

Br J Cancer. 2005 Jan 17;92(1):15-20. doi: 10.1038/sj.bjc.6602268.

Authors

F M Wachters¹, H J M Groen, B Biesma, F M N H Schramel, P E Postmus, J A Stigt, E F Smit

Affiliation

¹ Department of Pulmonary Diseases, University Hospital Groningen, PO Box 30.001, 9700 RB Groningen, The Netherlands.

Abstract

Response rate and toxicity of second-line therapy with docetaxel (75 mg m(-2)) or docetaxel, irinotecan, and lenogastrim (60 mg m(-2), 200 mg m(-2), and 150 microg m(-2) day(-1), respectively) were compared in 108 patients with stage IIIb-IV non-small-cell lung cancer. Addition of irinotecan to docetaxel does not improve response rate, and increases gastrointestinal toxicity.

Publication types

Clinical Trial
Clinical Trial, Phase II
Comparative Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

MeSH terms

Adolescent
Adult
Aged
Antineoplastic Combined Chemotherapy Protocols / adverse effects
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Camptothecin / administration & dosage*
Camptothecin / analogs & derivatives*
Carcinoma, Non-Small-Cell Lung / drug therapy*
Carcinoma, Non-Small-Cell Lung / mortality
Disease-Free Survival
Docetaxel
Female
Humans
Irinotecan
Lung Neoplasms / drug therapy*
Male
Middle Aged
Taxoids / administration & dosage*
Taxoids / adverse effects

Substances

Taxoids
Docetaxel
Irinotecan
Camptothecin